Mission Produce, Inc.
AVO screens expensive for a low-margin produce distributor whose near-term rebound is real but already too fully priced at 39.63x FY2025 EPS with execution risk still elevated after two straight -85.7% EPS misses and a synergy story that mostly sits in FY2027.
AVO is being valued like a cleaner compounder than it is. The business just posted FY2025 revenue of $1.4B, up 21.8%, but EPS collapsed 89.7% to $0.53. That is the core issue. Investors can point to volume growth, category expansion, and a better back half, but a company with 5.2% operating margin, 3.1% net margin, and roughly flat free cash flow should not command 39.63x earnings unless earnings quality is clearly inflecting higher and staying there.
The near-term earnings setup is better than the trailing numbers suggest. Management guided to $28M-$32M of Q3 EBITDA and $84M-$88M for 2H FY26, a major step up from $7.1M in Q2, helped by normalized sizing curves, improving per-unit margins, a stronger Peru crop of 120M-130M lbs, and partial Calavo contribution in Q3 with more in Q4. That likely means the worst quarter is past. The problem is price. At $12.87, with the stock only 17.1% below its 52-week high and basically on its 200-day average, the market is already leaning into that rebound.
The second leg of the bear case is that the most important strategic benefit, the Calavo synergy story, is not really a FY2026 event. Management says it sees $25M annualized cost synergies within 18 months and that Q4 FY26 is the starting point. That means the market is being asked to pay up today for a synergy curve that mostly belongs to FY2027, while the current-year evidence still includes two straight -85.7% EPS misses. Execution can improve, but recent credibility is not high enough to pay a premium multiple for promises.
What the case depends on is simple. First, avocado margins actually have to normalize, not just bounce for one quarter. Second, Calavo integration has to convert into measurable EBITDA and then into cash. Third, the company has to prove that secular avocado demand can overcome commodity pricing volatility rather than simply masking it with volume. If those three happen, downside is limited and the stock can hold in the low-to-mid teens. If any one slips, the valuation gives little cushion. That asymmetry keeps the rating at SELL.
Peru volumes, normalized sizing, and an early synergy ramp drive a cleaner earnings recovery than expected and keep the stock near the upper end of its 52-week range.
2H EBITDA improves broadly as guided, but the stock de-rates toward the engine value as investors weigh thin margins and peer-relative overvaluation.
Q3 or Q4 misses the rebound path, avocado pricing stays weak, and Calavo synergies slip, pushing the market toward a lower commodity-distributor multiple.
No analyst coverage available to cross-check.
The market is like a large movie theater with a small door.
Forward earnings should improve sharply from the depressed $0.53 FY2025 EPS base, but the stock is already priced for a large part of that normalization given a trailing 39.63x P/E and a share price only 17.1% below the 52-week high. The moat looks serviceable today, rooted in sourcing relationships, ripening infrastructure, and global origin diversity, but over 3 to 5 years it is not obviously strengthening because this remains a commodity-adjacent distribution business where AI mostly helps optimize forecasting, logistics, and inventory rather than creating pricing power. Regulation and food-safety compliance remain table stakes, not differentiators, while secular avocado demand is favorable but unlikely to offset structurally thin margins if price and fruit-size volatility persists. That combination supports caution: the company is headed into better EBITDA, but not into a business model that deserves a premium earnings multiple.
- Valuation is stretched at 39.63x P/E versus 12.8x peer average, while the quant base target is $10.73, or -16.6% from $12.87.
- FY2025 revenue grew 21.8% to $1.4B, but EPS fell 89.7% to $0.53, showing volume growth is not converting cleanly into earnings.
- Management guides to $84M-$88M 2H FY26 EBITDA after only $7.1M Q2 EBITDA, implying a sharp rebound that must execute almost perfectly.
- Second-half guidance is materially better: Q3 FY26 adjusted EBITDA $28M-$32M and 2H FY26 EBITDA $84M-$88M, versus just $7.1M in Q2, as fruit sizing normalizes and Peru ramps.
- Calavo closed on May 28, and management targets $25M annualized cost synergies within 18 months, with first benefit starting in Q4 FY26 and ramping through FY2027.
- Category demand remains healthy despite price volatility, with 1.6M new U.S. households entering avocados and industry volumes expected up 5% to 10% in Q3 FY26.
- Balance-sheet risk is manageable rather than acute, with Debt/EBITDA 2.06x, Debt/Equity 0.38, and a 1.91 current ratio.
- The business earns too little for the current multiple: FY2025 operating margin was only 5.2% and net margin 3.1%, yet the stock trades at 39.63x earnings.
- Recent execution has weakened, with consecutive EPS misses on 2026-03-12 and 2026-06-08, both at $0.01 versus $0.07 expected, or -85.7% each.
- Q2 exposed how fragile earnings are to pricing and mix, with revenue down 24% y/y, avocado prices down 36% per unit, and gross margin only 7.0% after spot buys for core sizes.
- Free cash generation is thin at $-0.0B while FY26 capex is still about $45M, limiting downside protection if the recovery slips.
| Metric | Value | Context |
|---|---|---|
| Current price | $12.87 | Reference price for rating and scenario work |
| Quant price target | $10.73 | -16.6% vs current, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $1.4B | +21.8% YoY, solid demand but not translating into earnings |
| FY2025 EPS | $0.53 | -89.7% YoY, key reason valuation looks stretched |
| Operating margin | 5.2% | Down from 5.3% prior FY, still very thin for current P/E |
| P/E | 39.63x | Versus peer average 12.8x, with wide peer dispersion |
| P/S | 0.72x | Near peer average 0.7x, suggesting the premium is in earnings expectations |
| Leverage | Debt/EBITDA 2.06x | Manageable balance sheet, not a distress story |
| Q2 FY26 adjusted EBITDA | $7.1M | On $290.9M revenue, margin about 2.4%, well below the level needed to justify the stock |
| 2H FY26 EBITDA guidance | $84M-$88M | Sharp rebound implied, central debate in the stock |
| Short interest | 8.96% | 4.73M shares, 4.1 days-to-cover, enough for earnings volatility |
| 52-week position | -17.1% vs $15.53 high | Not washed out, despite recent operating volatility |
The biggest risk to the short case is that management actually delivers the guided $84M-$88M 2H FY26 EBITDA and begins pulling forward confidence in the $25M synergy program, which could support a valuation above what current trailing EPS suggests.
Fiscal 2026 Q3 earnings on September 8, 2026, with the key tell being whether EBITDA lands inside the $28M-$32M range and whether early Calavo integration supports a stronger Q4 setup.
The ownership base is concentrated enough to matter, with top-3 institutions holding 42.4% and insiders owning 39.7%, which can support stability but also reduces effective float. Short interest is notable at 8.96%, or 4.73M shares, with 4.1 days-to-cover, so a good quarter can squeeze, but the options backdrop is only mildly supportive, with positive GEX and zero-gamma at $12.29, just below spot. Net, positioning can amplify earnings-day moves, but it does not change the underlying valuation problem.
Avocados are clearly the core earnings driver, with blueberries and mangoes additive but smaller based on call commentary.
Q2 avocado volume grew 15%, but lower pricing, down 36% per unit, compressed profits.
Q4 FY26 should benefit from higher blueberry yields, but this segment has shown price sensitivity in prior guidance.
Sourcing spans Mexico, California, and Peru, with Peru crop forecast at 120M-130M lbs for FY26 and about 20% above last year.
Back-half outlook improved with $84M-$88M 2H EBITDA as Q2 margin pressure normalizes.
Management's operating calls have been mixed, which argues for only moderate credibility. On the positive side, FY24 guidance around capex proved disciplined, with prior guidance of $40M-$45M then and current FY26 capex still around $45M, and the business did execute a strong stretch of beats from late 2024 through FY2025, including +250%, +900%, +300%, +100%, and +34.8% versus consensus. But the more recent record is weaker: the last two reported quarters both missed badly at $0.01 EPS versus $0.07 expected, and the current rebound case depends on management's assertion that "The supply of fruit and the sizing curves are now normalized and per-unit margins are recovering." The strategic direction has also shifted from balance-sheet repair, where in 2024 management said "Debt paydown remains our near-term priority," toward acquisition integration after the Calavo close. That is not necessarily wrong, but it does raise the bar on execution because promised value now rests on $25M annualized synergies within 18 months that are only expected to start showing in Q4 FY26.
The supply of fruit and the sizing curves are now normalized and per-unit margins are recovering.
Our relationships with customers are solid, and we expect to deliver strong performance the remainder of the year.
Consolidated fiscal third quarter adjusted EBITDA is expected in the range of $28 to $32 million, including the partial quarter contribution from the Calavo acquisition.
Consolidated second half adjusted EBITDA is expected in the range of $84 to $88 million, reflecting the drivers I mentioned for Q3, plus Q4 contributions from a full quarter of Calavo results, higher blueberry yields, and improving avocado margins.
We continue to see a minimum of $25 million of annualized cost synergies achievable within 18 months of close with meaningful upside potential.
Mission's edge is operational rather than brand-driven. It has global sourcing relationships, ripening and distribution infrastructure, and scale with retail customers that help it move fruit reliably across Mexico, California, and Peru. That moat is real but not deep: it improves service levels and asset utilization, yet it does not prevent margin compression when avocado pricing, fruit size, or procurement timing goes wrong, as seen in the recent 7.0% gross margin quarter.
Capital allocation looks functional, not shareholder-friendly. Free cash flow is essentially $-0.0B, there are no buybacks, no dividend, and FY26 capex is guided around $45M, so cash is still being directed toward operating capacity and integration rather than direct returns. The balance sheet can support that, with 2.06x Debt/EBITDA, but the lack of meaningful free cash generation lowers strategic flexibility.
AVO rates a SELL. The business is likely headed into a better half, but the stock already reflects too much of that improvement for a company with 39.63x P/E, 5.2% operating margin, and a fresh record of two major misses. The attractive part of the story, Calavo synergies and a cleaner sourcing mix, is mostly a FY2027 bridge, not a near-term cushion. A move to a more positive stance would require evidence that EBITDA recovery is converting into durable EPS and free cash flow, plus a materially lower entry price. Until then, the risk-reward still leans down toward the $10.73 base case.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. AVO rates a SELL at Medium conviction. The company has a credible second-half EBITDA rebound underway, but the stock at $12.87 already discounts a lot of that recovery while the underlying business still carries thin economics, 5.2% operating margin, flat free cash flow, and peer-relative valuation that is hard to defend at 39.63x earnings versus a 12.8x peer average. The setup is not distressed enough to offset the risk that avocado pricing stays soft and Calavo synergies arrive later than hoped.
Investment Thesis
AVO is being valued like a cleaner compounder than it is. The business just posted FY2025 revenue of $1.4B, up 21.8%, but EPS collapsed 89.7% to $0.53. That is the core issue. Investors can point to volume growth, category expansion, and a better back half, but a company with 5.2% operating margin, 3.1% net margin, and roughly flat free cash flow should not command 39.63x earnings unless earnings quality is clearly inflecting higher and staying there.
The near-term earnings setup is better than the trailing numbers suggest. Management guided to $28M-$32M of Q3 EBITDA and $84M-$88M for 2H FY26, a major step up from $7.1M in Q2, helped by normalized sizing curves, improving per-unit margins, a stronger Peru crop of 120M-130M lbs, and partial Calavo contribution in Q3 with more in Q4. That likely means the worst quarter is past. The problem is price. At $12.87, with the stock only 17.1% below its 52-week high and basically on its 200-day average, the market is already leaning into that rebound.
The second leg of the bear case is that the most important strategic benefit, the Calavo synergy story, is not really a FY2026 event. Management says it sees $25M annualized cost synergies within 18 months and that Q4 FY26 is the starting point. That means the market is being asked to pay up today for a synergy curve that mostly belongs to FY2027, while the current-year evidence still includes two straight -85.7% EPS misses. Execution can improve, but recent credibility is not high enough to pay a premium multiple for promises.
What the case depends on is simple. First, avocado margins actually have to normalize, not just bounce for one quarter. Second, Calavo integration has to convert into measurable EBITDA and then into cash. Third, the company has to prove that secular avocado demand can overcome commodity pricing volatility rather than simply masking it with volume. If those three happen, downside is limited and the stock can hold in the low-to-mid teens. If any one slips, the valuation gives little cushion. That asymmetry keeps the rating at SELL.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $12.87 | Reference price for rating and scenario work |
| Quant price target | $10.73 | -16.6% vs current, Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $1.4B | +21.8% YoY, solid demand but not translating into earnings |
| FY2025 EPS | $0.53 | -89.7% YoY, key reason valuation looks stretched |
| Operating margin | 5.2% | Down from 5.3% prior FY, still very thin for current P/E |
| P/E | 39.63x | Versus peer average 12.8x, with wide peer dispersion |
| P/S | 0.72x | Near peer average 0.7x, suggesting the premium is in earnings expectations |
| Leverage | Debt/EBITDA 2.06x | Manageable balance sheet, not a distress story |
| Q2 FY26 adjusted EBITDA | $7.1M | On $290.9M revenue, margin about 2.4%, well below the level needed to justify the stock |
| 2H FY26 EBITDA guidance | $84M-$88M | Sharp rebound implied, central debate in the stock |
| Short interest | 8.96% | 4.73M shares, 4.1 days-to-cover, enough for earnings volatility |
| 52-week position | -17.1% vs $15.53 high | Not washed out, despite recent operating volatility |
Financial Strength
The balance sheet is acceptable, not a reason to avoid the name by itself. Debt/Equity of 0.38, Debt/EBITDA of 2.06x, and a 1.91 current ratio give the company room to absorb volatility and integrate Calavo without immediate financing stress. The weaker read is on cash generation and margin resilience: free cash flow is essentially flat, the business is still spending about $45M of capex in FY26, and recent profitability showed how quickly earnings can compress when pricing and size mix move the wrong way. This is a stable enough balance sheet attached to a structurally unstable earnings stream.
Competitive Position
Mission's edge is operational rather than brand-driven. It has global sourcing relationships, ripening and distribution infrastructure, and scale with retail customers that help it move fruit reliably across Mexico, California, and Peru. That moat is real but not deep: it improves service levels and asset utilization, yet it does not prevent margin compression when avocado pricing, fruit size, or procurement timing goes wrong, as seen in the recent 7.0% gross margin quarter.
Management & Guidance
Current guidance is ambitious and internally coherent, but it asks investors to underwrite a very steep recovery. Management is guiding Q3 adjusted EBITDA of $28M-$32M and 2H EBITDA of $84M-$88M, with Peru volumes at 120M-130M lbs, industry volumes up 5% to 10% in Q3, and avocado pricing down 15% versus the prior year. The bridge relies on normalized fruit sizing, better sourcing mix as supply shifts from Mexico to California and Peru, and no meaningful synergy help until Q4. After a long streak of beats, the company has now posted two sharp misses in a row, so guidance should be treated as plausible but not bankable until Q3 proves the margin recovery is real.
Segment Analysis
- Product mix (Not disclosed in the provided data): Avocados are clearly the core earnings driver, with blueberries and mangoes additive but smaller based on call commentary.
- Avocados (Majority of revenue): Q2 avocado volume grew 15%, but lower pricing, down 36% per unit, compressed profits.
- Blueberries and other (Minority of revenue): Q4 FY26 should benefit from higher blueberry yields, but this segment has shown price sensitivity in prior guidance.
- Geography (Revenue split not disclosed in the provided data): Sourcing spans Mexico, California, and Peru, with Peru crop forecast at 120M-130M lbs for FY26 and about 20% above last year.
Capital Allocation
Capital allocation looks functional, not shareholder-friendly. Free cash flow is essentially $-0.0B, there are no buybacks, no dividend, and FY26 capex is guided around $45M, so cash is still being directed toward operating capacity and integration rather than direct returns. The balance sheet can support that, with 2.06x Debt/EBITDA, but the lack of meaningful free cash generation lowers strategic flexibility.
Management Execution & Track Record
Management's operating calls have been mixed, which argues for only moderate credibility. On the positive side, FY24 guidance around capex proved disciplined, with prior guidance of $40M-$45M then and current FY26 capex still around $45M, and the business did execute a strong stretch of beats from late 2024 through FY2025, including +250%, +900%, +300%, +100%, and +34.8% versus consensus. But the more recent record is weaker: the last two reported quarters both missed badly at $0.01 EPS versus $0.07 expected, and the current rebound case depends on management's assertion that "The supply of fruit and the sizing curves are now normalized and per-unit margins are recovering." The strategic direction has also shifted from balance-sheet repair, where in 2024 management said "Debt paydown remains our near-term priority," toward acquisition integration after the Calavo close. That is not necessarily wrong, but it does raise the bar on execution because promised value now rests on $25M annualized synergies within 18 months that are only expected to start showing in Q4 FY26.
Positioning & Flows
The ownership base is concentrated enough to matter, with top-3 institutions holding 42.4% and insiders owning 39.7%, which can support stability but also reduces effective float. Short interest is notable at 8.96%, or 4.73M shares, with 4.1 days-to-cover, so a good quarter can squeeze, but the options backdrop is only mildly supportive, with positive GEX and zero-gamma at $12.29, just below spot. Net, positioning can amplify earnings-day moves, but it does not change the underlying valuation problem.
Bull Case
- Second-half guidance is materially better: Q3 FY26 adjusted EBITDA $28M-$32M and 2H FY26 EBITDA $84M-$88M, versus just $7.1M in Q2, as fruit sizing normalizes and Peru ramps.
- Calavo closed on May 28, and management targets $25M annualized cost synergies within 18 months, with first benefit starting in Q4 FY26 and ramping through FY2027.
- Category demand remains healthy despite price volatility, with 1.6M new U.S. households entering avocados and industry volumes expected up 5% to 10% in Q3 FY26.
- Balance-sheet risk is manageable rather than acute, with Debt/EBITDA 2.06x, Debt/Equity 0.38, and a 1.91 current ratio.
Bear Case
- The business earns too little for the current multiple: FY2025 operating margin was only 5.2% and net margin 3.1%, yet the stock trades at 39.63x earnings.
- Recent execution has weakened, with consecutive EPS misses on 2026-03-12 and 2026-06-08, both at $0.01 versus $0.07 expected, or -85.7% each.
- Q2 exposed how fragile earnings are to pricing and mix, with revenue down 24% y/y, avocado prices down 36% per unit, and gross margin only 7.0% after spot buys for core sizes.
- Free cash generation is thin at $-0.0B while FY26 capex is still about $45M, limiting downside protection if the recovery slips.
Valuation & Price Target
Engine price target $10.73 (-16.6% vs current), Medium confidence.
- P/E Multiple: $7.78 (21% weight)
- PEG (growth-adjusted): $10.46 (20% weight)
- P/S Multiple: $11.19 (20% weight)
- Quality-adjusted: $13.57 (20% weight)
This rating aligns with the quant baseline SELL. The engine's $10.73 target already gives some credit to quality-adjusted and sales-based methods, but the stock still looks hard to own at $12.87 because FY2025 EPS was only $0.53, operating margin only 5.2%, and peer P/E dispersion is wide at 3.0x, which weakens confidence in any bullish peer-multiple argument. A divergence toward BUY would require stronger evidence that the guided $84M-$88M 2H FY26 EBITDA translates into durable EPS and free cash flow, not just a short rebound from an unusually weak Q2. There is no analyst coverage to anchor against, which removes a sentiment cross-check rather than creating one.
Risk Assessment
Risk score 38/100 (Low). The biggest risk to the short case is that management actually delivers the guided $84M-$88M 2H FY26 EBITDA and begins pulling forward confidence in the $25M synergy program, which could support a valuation above what current trailing EPS suggests.
The Bottom Line
AVO rates a SELL. The business is likely headed into a better half, but the stock already reflects too much of that improvement for a company with 39.63x P/E, 5.2% operating margin, and a fresh record of two major misses. The attractive part of the story, Calavo synergies and a cleaner sourcing mix, is mostly a FY2027 bridge, not a near-term cushion. A move to a more positive stance would require evidence that EBITDA recovery is converting into durable EPS and free cash flow, plus a materially lower entry price. Until then, the risk-reward still leans down toward the $10.73 base case.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr